PP
UTHR icon

Paloma Partners’s United Therapeutics UTHR Stock Holding History

Paloma Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,140
Closed -$1.86M – 2302
2021
Q1 		$1.86M Buy
+11,140
New +$1.86M 0.04% 433
2020
Q3 		– Sell
-39,744
Closed -$4.81M – 2484
2020
Q2 		$4.81M Buy
+39,744
New +$4.47M 0.08% 307
2020
Q1 		– Sell
-3,118
Closed -$275K – 2102
2019
Q4 		$275K Sell
3,118
-9,981
-76% -$878K ﹤0.01% 1805
2019
Q3 		$1.04M Buy
+13,099
New +$1.05M 0.02% 717
2019
Q2 		– Sell
-2,314
Closed -$272K – 2205
2019
Q1 		$272K Buy
+2,314
New +$270K 0.01% 1354
2018
Q4 		– Sell
-2,212
Closed -$283K – 1794
2018
Q3 		$283K Sell
2,212
-1,888
-46% -$234K 0.01% 1248
2018
Q2 		$464K Sell
4,100
-2,216
-35% -$244K 0.01% 1069
2018
Q1 		$710K Sell
6,316
-444
-7% -$56.4K 0.01% 1174
2017
Q4 		$1M Sell
6,760
-6,575
-49% -$836K 0.01% 1036
2017
Q3 		$1.56M Buy
13,335
+5,277
+65% +$674K 0.02% 893
2017
Q2 		$1.04M Sell
8,058
-2,543
-24% -$317K 0.01% 1174
2017
Q1 		$1.44M Sell
10,601
-5,124
-33% -$776K 0.02% 1013
2016
Q4 		$2.26M Buy
15,725
+7,294
+87% +$931K 0.02% 604
2016
Q3 		$996K Sell
8,431
-24,923
-75% -$2.99M 0.01% 1021
2016
Q2 		$3.53M Buy
33,354
+26,053
+357% +$2.91M 0.04% 392
2016
Q1 		$814K Sell
7,301
-27,655
-79% -$3.5M 0.01% 1019
2015
Q4 		$5.47M Buy
34,956
+32,709
+1,456% +$4.76M 0.14% 110
2015
Q3 		$295K Sell
2,247
-5,879
-72% -$943K 0.01% 1289
2015
Q2 		$1.41M Sell
8,126
-10,658
-57% -$1.92M 0.03% 585
2015
Q1 		$3.24M Buy
+18,784
New +$2.86M 0.09% 187
2014
Q4 		– Sell
-33,025
Closed -$4.25M – 1381
2014
Q3 		$4.25M Buy
33,025
+29,257
+776% +$3.02M 0.2% 115
2014
Q2 		$333K Buy
+3,768
New +$362K 0.01% 763
2013
Q3 		– Sell
-4,739
Closed -$311K – 1198
2013
Q2 		$311K Buy
+4,739
New +$305K 0.02% 638

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Paloma Partners's UTHR Position: Q2 2021 in Review

Paloma Partners sold out of United Therapeutics (UTHR) in Q2 2021, closing a stake of 11,140 shares — an estimated $1.86M sold.

Paloma Partners first reported a position in UTHR in Q2 2013 and held it in 23 quarters. The position peaked at $5.47M in Q4 2015. 402 funds tracked by Wall St. Rank hold UTHR as of Q2 2021.

  • Paloma Partners reported no remaining United Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Paloma Partners sold 11,140 United Therapeutics shares in Q2 2021, an estimated $1.86M.
  • Paloma Partners first reported a position in United Therapeutics in Q2 2013 and held it in 23 quarters.
  • Paloma Partners's United Therapeutics position peaked at $5.47M in Q4 2015.
  • 402 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2021.

Based on Paloma Partners's 13F filing for Q2 2021, filed 16 Aug 2021.